In the USA there are an estimated 2 million patients with a long-term urinary catheter. The majority of these patients are elderly, frail and living in the community. Urinary catheters are prone to complications including blockage, infection and haematuria. Catheter outputs are poorly monitored and approximately 40% of catheterised patients attend hospital at least once a year with a catheter-associated complication. These represent a significant burden on the healthcare system. We have developed a device that fits between the catheter and the drainage bag that continuously records urine output and transmits it to a cloud based system. The data are then analysed, complications are identified early and the appropriate clinician can be alerted. This paper reports on the results of a trial that demonstrates the ability of the device to identify catheter-related complications in comparison to current methods.
INTRODUCTION AND OBJECTIVES:
In the USA there are an estimated 2 million patients with a long-term urinary catheter. The majority of these patients are elderly, frail and living in the community. Urinary catheters are prone to complications including blockage, infection and haematuria. Catheter outputs are poorly monitored and approximately 40% of catheterised patients attend hospital at least once a year with a catheter-associated complication. These represent a significant burden on the healthcare system. We have developed a device that fits between the catheter and the drainage bag that continuously records urine output and transmits it to a cloud based system. The data are then analysed, complications are identified early and the appropriate clinician can be alerted. This paper reports on the results of a trial that demonstrates the ability of the device to identify catheter-related complications in comparison to current methods.
METHODS: This bench trial was conducted to compare the ability of the device to correctly identify three properties of urine: Urine Specific Gravity (USG), Haematuria and Infection. 120 patient samples were taken and graded from 0-5 by conventional means of urine analysis. USG was ascertained via dipstick analysis and graded 0-5 with 0 being USG less than 1.005 and 5 being greater than 1.025. Haematuria was measured by a combination of dipstick and visual analogue score, with 0 being dipstick negative and 5 being frank haematuria with clots. Infection was also measured in a similar manner with 0 being dipstick negative and 5 being cloudy, turgid urine.
These samples were then fed through a standard foley catheter at a rate of approximately 1ml/min where they were electronically analysed by the device and recorded. The results were then graphed and compared to the initial 'bedside' analysis. Comparative statistical analysis was performed via the Chi-Squared Test.
RESULTS: Statistical analysis showed that the device was able to identify gross changes in urine for each of the three variables, p<0.05 for all three. It was more consistent at identifying gradual changes in USG and haematuria than in infection. It was limited however in identifying multivariant characteristics (ie gross haematuria with infection) but we are confident that further analysis of a greater array of samples in addition to more advanced analytical techniques will improve this.
CONCLUSIONS: This trial concludes that the device can identify catheter related complications with a similar accuracy to conventional 'bedside' methods. Its intended use is to monitor elderly catheterised patients and alert their doctors and carers to potential problems and we believe that this trial shows it has the potential to be of benefit. A multi-center trial is currently recruiting in order to show the clinical predictive value of continuous urine monitoring. METHODS: UAS deployment force was measured with a UAS-FS, developed in collaboration with engineers at our institution (Figure 1 ). Continuous UAS-FS measurements were recorded from the urethral meatus until either the UAS reached the desired ureteral deployment site or 10 Newtons (N) was recorded. A 16 Fr UAS was used in each initial attempt. Fluoroscopic images were obtained at 2 N, 4 N, 6 N, 8 N, and 10 N. In general, if 8 N was reached, the 16 Fr UAS was exchanged for a 14 Fr or 11 Fr UAS. Ureteroscopic assessment of the ureter at the end of each case was quantitated using the post-ureteroscopic lesion scale (PULS).
RESULTS: UAS deployment force was measured in 72 ureters among 65 patients. The 16 Fr UAS was deployed in 51 ureters (71%) at a maximal force of 5.4 N (1.9-11.6). In the remaining cases, a 14 Fr or 11 Fr UAS was passed in 19% and 10% with a maximal force of 4.6 N (1.4-9.1) and 3.1 N (1.2-5.0), respectively (p[0.08). Maximum peak force was most commonly recorded (31%) at the distal ureter. PULS 0, 1, and 2 were recorded in 31%, 36%, and 15% of cases, respectively (not recorded in 17%) ( Table 1) . A single PULS 3 was noted following deployment of a 14 Fr UAS at a peak pressure of 8.9 N. Of note, when the force applied was <5 N, the PULS score was consistently 1. On multivariate analysis, successful deployment of a 16 Fr UAS was associated with prestented ureters (p[0.04). Preoperative treatment with tamsulosin was not associated with lower PULS (p[0.32), lower peak force applied (p[0.39), or with an increase in deployment of the 16 Fr UAS (p[0.45) .
CONCLUSIONS: Using an UAS-FS, ureteral access deployment force could be continuously measured in the clinical setting. Limiting the deployment force to <5 N consistently resulted in a PULS score of 1.
A single-use flexible cystoscope with integrated grasper (Isiris, Coloplast, Denmark) has recently become commercially available. The objective of this study was to compare the costs of stent removal in an outpatient clinical environment between the single-use Isiris system (Coloplast, Denmark) to our existing approach using a reusable cystoscope and stent grasper.
METHODS: The number of stent removal procedures at our tertiary center was recorded as a proportion of all cystoscopic procedures performed between February 2016 and February 2017. Elements included in the micro-cost assessment included: the original purchasing price of an Olympus digital reusable cystoscope, repair fee (based on a one year contract), sterilization equipment and accessory costs, reprocessing costs of the cystoscope, and labor costs. Costs were Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e77
